Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 3, 2007

Phyton Acquires Glyco-Engineering Technique

  • Phyton Biotech acquired Dow Chemical’s technology and intellectual property platform for the engineering of glycosylation in pharmaceutical protein products.

    This transaction will be enhanced through a research collaboration with the Dutch research institute Plant Research International, part of Wageningen University & Research Centre and one of the innovators of the technology platform, according to Phyton.

    The Dow agreement coincides with the installation of a second 75,000-liter bioreactor at Phyton’s German cell fermentation facility.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »